Bacil Pharma (524516) Q1 25/26 earnings summary

Executive summary

• Unaudited financial results for the quarter ended 30th June 2025 were approved, showing a significant turnaround in profitability compared to the same quarter last year.

• The resignation of the Manager, Mr. Ganpat Dhondu Salekar, was accepted by the Board.

Financial highlights

• Revenue from operations for Q1 FY26 was ₹100.25 lakhs, unchanged from the previous quarter and up from ₹66.14 lakhs year-over-year.

• Profit after tax for the quarter was ₹66.87 lakhs, a sharp increase from ₹1.56 lakhs in the previous quarter and a loss of ₹3.40 lakhs in the same quarter last year.

• EPS (basic and diluted) for the quarter stood at ₹0.48, compared to ₹0.02 in the previous quarter and a loss of ₹0.06 year-over-year.

• Other income contributed ₹8.77 lakhs to total revenue.

• Total expenses for the quarter were ₹10.89 lakhs, up from ₹7.22 lakhs in the previous quarter.

Outlook and guidance

• Statutory auditor issued an unmodified opinion on the unaudited results, with certain emphasis of matter regarding fund application and related party transactions.